

Hikma Ventures Participates in CAD4.0 million Series A Financing Round for SeamlessMD to Expand Digital Patient Engagement Leadership

London, August 26, 2020 – Hikma Pharmaceuticals PLC (Hikma) announces that its venture capital arm, [Hikma Ventures](#) has participated in a CAD4.0 million Series A round of financing for [SeamlessMD](#). The round was led by MEDTEQ, bringing the company's total funding to CAD7.4 million. Anges Québec, AIoT Health, and health IT entrepreneur Sanjay Malaviya also participated in the oversubscribed round.

Toronto-based SeamlessMD is a leader in digital patient engagement and is used by UAB, Rush, Atrium Health and dozens of other leading health systems to engage, monitor, and stay connected with patients throughout a variety of healthcare journeys, including surgery, oncology, and chronic care. Patients can access digital care plans on their smartphones, tablets, or computers and be guided via reminders, interactive education, and progress tracking. Providers receive alerts, monitor patients remotely, and access analytics to deliver better care.

"We have been incredibly impressed by SeamlessMD's vision, category-leading clinical evidence, and best-in-class technology platform, and are excited to add them to the diverse portfolio of companies we have invested in that are utilizing digital health technology to improve outcomes for patients," said Hamzeh Abdul-Hadi, Principal at Hikma Ventures. "SeamlessMD has developed a proven model for health systems to improve patient outcomes at scale, and we are thrilled to support SeamlessMD in advancing their mission and expanding into new markets where Hikma operates to improve the quality of care."

Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals. Its priority is to identify and invest in emerging companies in the digital health space globally that have the potential to enhance Hikma's market intelligence and future pipeline.

"COVID-19 has accelerated the need for health systems to deliver digital care at scale. Since the pandemic started, we have been rapidly assisting health systems to adapt to the pandemic, including new solutions for COVID-19 digital screening, patient education, and digital pre-surgery monitoring to safely resume surgery," said Dr. Joshua Liu, MD, Co-Founder & CEO of SeamlessMD. "This investment from Hikma Ventures will be critical in enabling us to meet growing customer demand, expand our library of digital care plans and further develop our machine learning platform for risk prediction and optimizing patient outcomes. We are ecstatic to be supported by forward thinking, strategic healthcare investors such as Hikma Ventures who share our belief that the future of healthcare is digital."

SeamlessMD's financing follows a period of establishing category leadership, having become the first digital patient engagement platform to hold validated, turn-key integrations with leading electronic health record companies Epic and Cerner. SeamlessMD also remains the industry leader in clinical validation, with over 15 clinical studies across numerous specialties demonstrating significant results, including: cost reductions of \$1,000-\$2,000 per patient; reductions in hospital length of stay by 1-2 days; and reductions in hospital readmissions by 45%-72%.

-- ENDS --

Investor Enquiries

Hikma Ventures

Lana Ghanem
Managing Director, Hikma Ventures

lana@hikmaventures.com
+962 6 580 3100

Media Enquiries

Hikma Pharmaceuticals PLC

Steve Weiss
David Belian
US Communications and Public Affairs

+1 732 720 2830/ +1 732 788 8279
+1 732 720 2814/+1 848 254 4875
uscommunications@hikma.com



About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and Ba1/stable Moody's)

About Hikma Ventures

Founded in August 2015, Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals. Hikma Ventures invests in global start-ups where Hikma's expertise can accelerate revenue growth and enhance value creation by providing ventures with access to the resources of a multinational pharmaceutical company. For more information, please visit www.hikmaventures.com.

About SeamlessMD

SeamlessMD provides the #1 digital patient engagement platform used by health systems to elevate the patient experience, improve outcomes and lower costs. Patients access digital care plans on their smartphones, tablets or computers and are guided through their health conditions or treatments via reminders, education and progress tracking. Providers receive alerts, monitor patients and access analytics to deliver better care. SeamlessMD is directly integrated with Epic and Cerner. Health systems such as Stanford Health Care, Rush University Medical Center and UAB Health System use SeamlessMD to improve patient satisfaction while reducing hospital length of stay, readmissions, and costs. For more information and to see SeamlessMD in action, please visit: www.seamless.md.